×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: ALS Mechanistic Pathway
mechanism
1,086 words
KG: ent-dise-93f3d65f
2026-04-01
kind:mechanism
section:mechanisms
state:published
evidence:strong
Contents
ALS Mechanistic Pathway
⚙
Mechanism Info
Name
ALS Mechanistic Pathway
Summary
Comprehensive pathway model of ALS molecular mechanisms
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
SASP-Mediated Complement Cascade Amplification
Score: 0.70
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Vagal Afferent Microbial Signal Modulation
Score: 0.52
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Transcriptional Autophagy-Lysosome Coupling
Score: 0.66
Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain A
Score: 0.51
Noradrenergic-Tau Propagation Blockade
Score: 0.51
Autophagosome Maturation Checkpoint Control
Score: 0.49
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44
VCP-Mediated Autophagy Enhancement
Score: 0.41
Palmitoylation-Targeted BACE1 Trafficking Disruptors
Score: 0.41
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38
Synaptic Vesicle Tau Capture Inhibition
Score: 0.34
Vocal Cord Neuroplasticity Stimulation
Score: 0.50
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.53
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
APOE-TREM2 Interaction Modulation
Score: 0.48
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.45
Mitochondrial Transfer Pathway Enhancement
Score: 0.44
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
Mitochondrial RNA Granule Rescue Pathway
Score: 0.40
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.40
Show 25 more
Related Analyses (30)
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed
What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed
What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the molecular signatures that distinguish protectiv
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 25 more
Related Experiments (30)
cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85
cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80
s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
validation · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
Experiment Index
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
TLR4 Antagonists for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Tirzepatide and Dual GIP/GLP-1 Agonists for Neurodegene
therapeutic · Pages share 3 hypotheses
SYK Kinase Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
STING Inhibitor Therapy in Neurodegeneration
therapeutic · Pages share 3 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapy for Ne
therapeutic · Pages share 3 hypotheses
Somatostatin Receptor Modulator Therapy in Neurodegener
therapeutic · Pages share 3 hypotheses
Advanced Neuroimmune Interface and Glial-Neuronal Cross
therapeutic · Pages share 3 hypotheses
Section 147 Neuroimmune Interface and Glial-Neuronal Cr
therapeutic · Pages share 3 hypotheses
RIPK1 Inhibitors for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Precision Medicine Approaches for Neurodegeneration
therapeutic · Pages share 3 hypotheses
P2X7 Receptor Antagonists for Neurodegeneration
therapeutic · Pages share 3 hypotheses
nfat-pathway-modulators-neurodegeneration
therapeutic · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
therapeutic · Pages share 3 hypotheses
Neuroinflammation Modulation Therapies for Neurodegener
therapeutic · Pages share 3 hypotheses
Show 10 more